EE200400010A - 4-[4-[4-(hüdroksüdifenüülmetüül)-1-piperidinüül]-1-hüdroksübutüül]-a,a-dimetüülben seenäädikhappe ja selle hüdrokloriidi uued kristalsed vormid - Google Patents

4-[4-[4-(hüdroksüdifenüülmetüül)-1-piperidinüül]-1-hüdroksübutüül]-a,a-dimetüülben seenäädikhappe ja selle hüdrokloriidi uued kristalsed vormid

Info

Publication number
EE200400010A
EE200400010A EEP200400010A EEP200400010A EE200400010A EE 200400010 A EE200400010 A EE 200400010A EE P200400010 A EEP200400010 A EE P200400010A EE P200400010 A EEP200400010 A EE P200400010A EE 200400010 A EE200400010 A EE 200400010A
Authority
EE
Estonia
Prior art keywords
hydroxydiphenylmethyl
hydroxybutyl
piperidinyl
hydrochloride
crystalline forms
Prior art date
Application number
EEP200400010A
Other languages
English (en)
Estonian (et)
Inventor
Satyanarayana Reddy M.
Thirumalai Rajan S.
V. Bhaskara Rao U.
Original Assignee
Dr. Reddy's Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd. filed Critical Dr. Reddy's Laboratories Ltd.
Publication of EE200400010A publication Critical patent/EE200400010A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200400010A 2001-06-18 2001-07-31 4-[4-[4-(hüdroksüdifenüülmetüül)-1-piperidinüül]-1-hüdroksübutüül]-a,a-dimetüülben seenäädikhappe ja selle hüdrokloriidi uued kristalsed vormid EE200400010A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN484MA2001 2001-06-18
PCT/US2001/023994 WO2002102777A2 (en) 2001-06-18 2001-07-31 NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE

Publications (1)

Publication Number Publication Date
EE200400010A true EE200400010A (et) 2004-02-16

Family

ID=34566868

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200400010A EE200400010A (et) 2001-06-18 2001-07-31 4-[4-[4-(hüdroksüdifenüülmetüül)-1-piperidinüül]-1-hüdroksübutüül]-a,a-dimetüülben seenäädikhappe ja selle hüdrokloriidi uued kristalsed vormid

Country Status (20)

Country Link
EP (2) EP2261209A1 (xx)
JP (2) JP2005507374A (xx)
KR (1) KR20040015734A (xx)
CN (1) CN100390145C (xx)
AU (1) AU2001278094B2 (xx)
BG (1) BG108435A (xx)
BR (1) BR0117054A (xx)
CA (2) CA2450858C (xx)
CO (1) CO5540340A2 (xx)
CZ (1) CZ20033358A3 (xx)
EE (1) EE200400010A (xx)
HU (1) HUP0401546A2 (xx)
IL (2) IL159266A0 (xx)
MX (1) MXPA03011728A (xx)
NZ (1) NZ530118A (xx)
PL (1) PL367632A1 (xx)
RU (1) RU2269516C2 (xx)
SK (1) SK15372003A3 (xx)
WO (1) WO2002102777A2 (xx)
ZA (1) ZA200309557B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366576A1 (en) * 2001-04-09 2005-02-07 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20040044038A1 (en) 2002-06-10 2004-03-04 Barnaba Krochmal Polymorphic form XVI of fexofenadine hydrochloride
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
EP1628959A2 (en) * 2004-04-26 2006-03-01 Teva Pharmaceutical Industries Ltd Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
JP2008514641A (ja) * 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
WO2007007347A1 (en) * 2005-07-07 2007-01-18 Wockhardt Limited Industrial process of fexofenadine hydrochloride with controlled side products
EP2105134A1 (en) 2008-03-24 2009-09-30 Ranbaxy Laboratories Limited Stable amorphous fexofenadine hydrochloride
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
JPH10500134A (ja) * 1994-05-18 1998-01-06 ヘキスト・マリオン・ルセル・インコーポレイテツド 抗ヒスタミン性ピペリジン誘導体の無水および水和形態、それらの多形態および擬似形態の製造方法
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
IN191492B (xx) 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
GB0018691D0 (en) * 2000-07-28 2000-09-20 Rolabo Sl Process

Also Published As

Publication number Publication date
CZ20033358A3 (en) 2004-04-14
WO2002102777A8 (en) 2003-10-30
CN1518540A (zh) 2004-08-04
BR0117054A (pt) 2004-07-27
CA2450858C (en) 2009-04-07
JP2008094848A (ja) 2008-04-24
SK15372003A3 (sk) 2004-08-03
EP2261209A1 (en) 2010-12-15
AU2001278094B2 (en) 2006-01-12
RU2004101045A (ru) 2005-06-27
RU2269516C2 (ru) 2006-02-10
IL159266A0 (en) 2004-06-01
CA2450858A1 (en) 2002-12-27
WO2002102777A3 (en) 2003-02-27
WO2002102777A2 (en) 2002-12-27
MXPA03011728A (es) 2004-07-08
IL159266A (en) 2010-11-30
CN100390145C (zh) 2008-05-28
PL367632A1 (en) 2005-03-07
BG108435A (en) 2004-12-30
NZ530118A (en) 2007-05-31
EP1399422A2 (en) 2004-03-24
JP2005507374A (ja) 2005-03-17
KR20040015734A (ko) 2004-02-19
CA2646802A1 (en) 2002-12-27
HUP0401546A2 (hu) 2004-12-28
ZA200309557B (en) 2004-09-14
CO5540340A2 (es) 2005-07-29

Similar Documents

Publication Publication Date Title
EE200400010A (et) 4-[4-[4-(hüdroksüdifenüülmetüül)-1-piperidinüül]-1-hüdroksübutüül]-a,a-dimetüülben seenäädikhappe ja selle hüdrokloriidi uued kristalsed vormid
LTC1463716I2 (lt) Pirolidino ir piperidino dariniai kaip NK1 antagonistai
NO20013538D0 (no) Piperidin, tetrahydropyridin og piperazinderivater, deres fremstilling og anvendelse
NO20000115D0 (no) Gastrokinetiske monocykliske benzamider av 3- eller 4- substituerte 4-(aminometyl)-piperidinderivater
NO20026125D0 (no) Tetrahydropyridin- eller piperidin-heterocykliske derivater
PL368827A1 (en) Piperidine derivatives useful as ccr5 antagonists
IL146707A0 (en) Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and its physiologically acceptable salts
ATE479681T1 (de) Substituierte piperidine
NO20043239D0 (no) Piperidinderivater
DK1505066T3 (da) Polymorf af 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-IL]-1-piperidinyl]ethyl]-alfa,alfa-dimethylbenzeneddikesyre
HUP0201673A3 (en) Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-alpha, alpha-dimethylbenzeneacetic acid
PL325264A1 (en) Novel derivatives of phenyl-alpha,alpha-dimethylacetic acid, method of obtaining such derivatives, method of obtaining a pharmaceutic agent, application of such derivatives and method of obtaining 4-{4-[4-(hydroxydiphenylmethyl)piperidin]-1-hydroxybutyl}-phenyl-alpha,alpha-dimethylacetic acid
NZ598718A (en) Polymorphic forms of manidipine
IS7901A (is) 4-(2-Fenýloxýfenýl)-píperidín eða -1,2,3,6-tetrahýdrópýridín afleiður sem serótónín endurupptöku hindrar
NZ306319A (en) 1-alkylphenyl substituted 4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butanol derivatives and medicaments
IL152570A0 (en) A process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-alpha, alpha-di methylbenzeneacetic acid
ATE344244T1 (de) Substituierte 4-phenyl-1-(1-phenyl-cyclohexyl)-1, 2,3,6-tetrahydropyridine
IL191460A0 (en) A process for the preparation of keto compounds
CY1107658T1 (el) Θειϊκο οξυ μονο-[3-({1-[2-(4-φθορο-φαινυλ)-αιθυλ]-πιπεριδιν-4-υλ}-υδροξυ-μεθυλ)-2-μεθοξυ-φαινυλ] εστερας
DE50209613D1 (de) In 3-position heterocyclisch substituierte piperidin-2,6-dione
TH86760B (th) การรวมกันที่รักษาโรคได้ ซึ่งประกอบด้วยตัวบล็อกช่องแคลเซียมชนิดไดไฮโดรไพริดีนที่ออกฤทธิ์ระยะยาว และสเททิน
SI1202967T1 (sl) Mono-(3-(1-(2-(4-fluoro-fenil)-etil)-piperidin-4-il)-hidroksi-metil)-2- metoksi-fenil)ester zveplove kisline
WO2005037756A3 (fr) Nouveaux procedes de preparation de l’acide 4-[4-(4-methoxymethoxy-4’-methyl-biphenyl-2-yl)-but-3-ene-(e)-1-ynyl]-benzoïque
FI5467U1 (fi) Amlodipiinin aspartaattijohdannainen
ATE551338T1 (de) Aminosulfonyl substituierte 4-(aminomethyl)- piperidine benzamide als 5ht4-antagonisten